+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • May 2023
  • GlobalData
  • ID: 4285130
FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

FibroGen Inc (FibroGen) is a biopharmaceutical company that discovers, and develops medicines for the treatment of anemia, cancer, and fibrotic disease. Its approved product includes roxadustat for the treatment of treatment of anemia associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. Its pipeline product includes pamrevlumab (FG-3019) for the treatment of idiopathic pulmonary fibrosis (IPF) and duchenne muscular dystrophy (DMD). The company has operations in the US, Hong Kong, Finland, Cayman Islands and China. FibroGen is headquartered in San Francisco, California, the US.

FibroGen Inc Key Recent Developments

  • May 08, 2023: FibroGen Reports First Quarter 2023 Financial Results
  • Feb 27, 2023: FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
  • Feb 17, 2023: FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
  • Nov 07, 2022: FibroGen Reports Third Quarter 2022 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • FibroGen Inc - Key Facts
  • FibroGen Inc - Key Employees
  • FibroGen Inc - Key Employee Biographies
  • FibroGen Inc - Major Products and Services
  • FibroGen Inc - History
  • FibroGen Inc - Company Statement
  • FibroGen Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • FibroGen Inc - Business Description
  • Other Break-up: Development and Other Revenue
  • Overview
  • Performance
  • Other Break-up: Drug Product
  • Overview
  • Performance
  • Other Break-up: License
  • Overview
  • Performance
  • Other Break-up: Product Revenue, Net
  • Overview
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • FibroGen Inc - Corporate Strategy
  • FibroGen Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • FibroGen Inc - Strengths
  • FibroGen Inc - Weaknesses
  • FibroGen Inc - Opportunities
  • FibroGen Inc - Threats
  • FibroGen Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • FibroGen Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 08, 2023: FibroGen Reports First Quarter 2023 Financial Results
  • Feb 27, 2023: FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
  • Feb 17, 2023: FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
  • Nov 07, 2022: FibroGen Reports Third Quarter 2022 Financial Results
  • Aug 08, 2022: FibroGen Reports Second Quarter 2022 Financial Results
  • May 26, 2022: FibroGen to Present at Jefferies Healthcare Conference
  • Feb 28, 2022: FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
  • Jan 04, 2022: FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • FibroGen Inc, Key Facts
  • FibroGen Inc, Key Employees
  • FibroGen Inc, Key Employee Biographies
  • FibroGen Inc, Major Products and Services
  • FibroGen Inc, History
  • FibroGen Inc, Subsidiaries
  • FibroGen Inc, Key Competitors
  • FibroGen Inc, Ratios based on current share price
  • FibroGen Inc, Annual Ratios
  • FibroGen Inc, Interim Ratios
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • FibroGen Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • FibroGen Inc, Performance Chart (2018 - 2022)
  • FibroGen Inc, Ratio Charts
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Vifor Pharma Management Ltd
  • Sandoz Inc
  • Pfizer Inc
  • Kyowa Kirin Co Ltd
  • Johnson & Johnson
  • GSK plc
  • Glycomantra Inc
  • F. Hoffmann-La Roche Ltd
  • Celgene Corp
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Amgen Inc
  • Akebia Therapeutics Inc
  • Acceleron Pharma Inc
  • 3SBio Inc
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • 3SBio Inc
  • Akebia Therapeutics Inc
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Glycomantra Inc
  • Kyowa Kirin Co Ltd
  • Pfizer Inc
  • GSK plc
  • Vifor Pharma Ltd
  • Celgene Corp
  • Sandoz Inc
  • Acceleron Pharma Inc
  • Amgen Inc